Connection

John Colwell to Hypoglycemic Agents

Back to Details
This is a "connection" page, showing publications John Colwell has written about Hypoglycemic Agents.
John Colwell
Connection Strength
0.636
Hypoglycemic Agents
  1. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care. 1998 Apr; 21(4):510-5.
    View in: PubMed
    Score: 0.119
  2. Should we use intensive insulin therapy after oral agent failure in type II diabetes? Diabetes Care. 1996 Aug; 19(8):896-8.
    View in: PubMed
    Score: 0.106
  3. The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM. Ann Intern Med. 1996 Jan 01; 124(1 Pt 2):131-5.
    View in: PubMed
    Score: 0.102
  4. Treatment for the procoagulant state in type 2 diabetes. Endocrinol Metab Clin North Am. 2001 Dec; 30(4):1011-30.
    View in: PubMed
    Score: 0.038
  5. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care. 2000 Sep; 23(9):1316-20.
    View in: PubMed
    Score: 0.035
  6. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Arch Intern Med. 1998 Dec 7-21; 158(22):2485-90.
    View in: PubMed
    Score: 0.031
  7. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care. 1998 Apr; 21(4):574-9.
    View in: PubMed
    Score: 0.030
  8. Multifactorial aspects of the treatment of the type II diabetic patient. Metabolism. 1997 Dec; 46(12 Suppl 1):1-4.
    View in: PubMed
    Score: 0.029
  9. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med. 1997 Jan 27; 157(2):181-8.
    View in: PubMed
    Score: 0.027
  10. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care. 1996 Dec; 19(12):1375-81.
    View in: PubMed
    Score: 0.027
  11. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care. 1995 Aug; 18(8):1113-23.
    View in: PubMed
    Score: 0.025
  12. Platelet plasminogen activator inhibitor 1 in patients with type II diabetes. Diabetes Care. 1994 Aug; 17(8):818-23.
    View in: PubMed
    Score: 0.023
  13. Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Hyperlipidemia in Diabetes Investigators. Diabetes Care. 1993 Jan; 16(1):37-44.
    View in: PubMed
    Score: 0.021
  14. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care. 2000 Oct; 23(10):1478-85.
    View in: PubMed
    Score: 0.009
  15. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). J Diabetes Complications. 1999 Sep-Dec; 13(5-6):307-13.
    View in: PubMed
    Score: 0.008
  16. Intrapancreatic perfusion of the antidiabetic sulfonylureas. Metabolism. 1956 Nov; 5(6 Part 2):749-56.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.